Evidence map›Paper›PMID 33534843›Full record

ArticlePloS one2021

Protection of dopamine neurons by CDNF and neurturin variant N4 against MPP+ in dissociated cultures from rat mesencephalon.

Juliann D Jaumotte, Mart Saarma, Michael J Zigmond

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Neurobiology of exercise in Parkinson's disease.Journal of Parkinson's disease · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Juliann D JaumotteDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, United States of America.ORCID 0000-0001-6124-7822
Mart SaarmaInstitute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.
Michael J ZigmondDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, United States of America.
University of Pittsburgh · USUniversity of Helsinki · FI

Funding

Mechanisms of Exercise-Induced Protection and Rescue in Models of Dopamine LossR01NS070825 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOFFER, BARRY J, ZIGMOND, MICHAEL J · 2011 to 2014
$2.3M
NEUROPLASTICITY IN DAMAGED CATECHOLAMINERGIC SYSTEMSP01NS019608 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SVED, ALAN F · 1985 to 2002
$2.1M
NINDS NIH HHS P01 NS019608NINDS NIH HHS R01 NS070825
6 · The paper itself

Abstract

Parkinson's disease is associated with the loss of dopamine (DA) neurons in ventral mesencephalon. We have previously reported that no single neurotrophic factor we tested protected DA neurons from the dopaminergic toxin 1-methyl-4-phenylpyridinium (MPP+) in dissociated cultures isolated from the P0 rat substantia nigra, but that a combination of five neurotrophic factors was protective. We now report that cerebral DA neurotrophic factor (CDNF) and a variant of neurturin (NRTN), N4, were also not protective when provided alone but were protective when added together. In cultures isolated from the substantia nigra, MPP+ (10 μM) decreased tyrosine hydroxylase-positive cells to 41.7 ± 5.4% of vehicle control. Although treatment of cultures with 100 ng/ml of either CDNF or N4 individually before and after toxin exposure did not significantly increase survival in MPP+-treated cultures, when the two trophic factors were added together at 100 ng/ml each, survival of cells was increased 28.2 ± 6.1% above the effect of MPP+ alone. In cultures isolated from the ventral tegmental area, another DA rich area, a higher dose of MPP+ (1 mM) was required to produce an EC50 in TH-positive cells but, as in the substantia nigra, only the combination of CDNF and N4 (100 ng/ml each) was successful at increasing the survival of these cells compared to MPP+ alone (by 22.5 ± 3.5%). These data support previous findings that CDNF and N4 may be of therapeutic value for treatment of PD, but suggest that they may need to be administered together.

Indexed as

1-Methyl-4-phenylpyridiniumAnimalsCells, CulturedCell SurvivalCHO CellsCricetulusDopamineDopamine Plasma Membrane Transport ProteinsDopaminergic NeuronsHumansMesencephalonNerve Growth FactorsNeuroprotective AgentsNeurturinNomifensineRats1-Methyl-4-phenylpyridiniumCDNF protein, humanDopamineDopamine Plasma Membrane Transport ProteinsNerve Growth FactorsNeuroprotective AgentsNeurturinNomifensineTritiumTyrosine 3-Monooxygenase

Identifiers

PMID33534843
PMCPMC7857574
OpenAlexW3126639184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.